Stoke Therapeutics (NASDAQ:STOK) Director Sells $1,321,076.82 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Adrian Krainer sold 33,243 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the completion of the sale, the director directly owned 283,302 shares in the company, valued at approximately $11,258,421.48. The trade was a 10.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK traded down $1.46 on Thursday, hitting $36.48. The company’s stock had a trading volume of 526,077 shares, compared to its average volume of 733,735. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $40.22. The company has a market capitalization of $2.08 billion, a PE ratio of 54.45 and a beta of 1.07. The company has a 50-day simple moving average of $32.57 and a 200 day simple moving average of $29.41.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of STOK. Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics during the fourth quarter valued at approximately $26,000. Harbour Investments Inc. increased its stake in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares during the period. Generali Investments Management Co LLC purchased a new position in shares of Stoke Therapeutics during the 3rd quarter valued at about $41,000. BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. HC Wainwright boosted their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Wolfe Research assumed coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price target on the stock. Canaccord Genuity Group raised their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Guggenheim started coverage on Stoke Therapeutics in a research report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price target for the company. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.25.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.